leisure time -WSS

leisure time

author：fashion 2025-09-29 20:51:23 - browse：8

Powdered ibogaine against a white background. — Tabernanthe iboga, the shrub that contains the psychedelic substance ibogaine. Wikimedia Commons

The psychedelic ibogaine is unlikely to ever receive approval as a treatment for opioid addiction, the federal government’s top addiction researcher said Thursday.

The remarks from Nora Volkow, the longtime director of the National Institute on Drug Abuse, serve as a cautionary note amid widespread enthusiasm about ibogaine, a naturally occurring substance that drug companies and researchers have increasingly cast as a potential paradigm-shifting addiction treatment.

But its potential cardiac side effects could stand in the way of receiving approval from the Food and Drug Administration, Volkow said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： What should King Charles tell the public about his cancer?

focus

WSS

What's changing in Medicare's open enrollment this year?

A revolution in caring for preterm infants

What's changing in Medicare's open enrollment this year?

Life sciences deals on track to hit lowest point since 2017

Humana CEO Bruce Broussard to step down in 2024

A fraught question for the kids of Alzheimer’s: Is it coming for us?

explore

leisure time

focus

Supreme Court strikes down use of affirmative action

A revolution in caring for preterm infants

As demand for Covid shots wanes, Moderna seeks its next success

To avoid data mishandling cases, universities eye AI and other tools

Bright Health sells Medicare Advantage business to Molina

Medicare threatens to cut off funding for HCA's Mission hospital

What does generative AI mean for health care? We asked experts

KalVista pill reduced swelling 'attacks' caused by genetic disease

Trump demands the U.S. pay no more for drugs than other countries … again

https://cbu01.alicdn.com/img/ibank/2017/311/963/4596369113_957508731.220x220xz.jpg

Wikipedia

European regulators consider appeal over Amylyx ALS drug

A fraught question for the kids of Alzheimer’s: Is it coming for us?

BioAge raises $170M for combination therapy with Zepbound

What we’ve learned from the Aduhelm mess

Takeaways from AdvaMed, the largest medical devices conference

Massive project maps cells in human brain in unprecedented detail

knowledge

focus

hotspot

knowledge